VRP Verona Pharma Plc

 
TIDMVRP 
 
   LONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq: VRNA) ("Verona Pharma"), a clinical stage biopharmaceutical 
company focused on respiratory diseases, is pleased to announce the 
appointment of Nplus1 Singer Advisory LLP (together with its associates, 
"N+1 Singer") as nominated adviser and UK corporate broker to the 
Company with immediate effect. 
 
   For further information contact: 
 
 
 
 
Verona Pharma plc                                          Tel: +44 (0)20 3283 4200 
 Jan-Anders Karlsson, Chief Executive Officer               mailto:info@veronapharma.com info@veronapharma.com 
 Victoria Stewart, Director of Communications 
                                                           ----------------------------------------------------------------------- 
N+1 Singer (Nominated Adviser and UK Broker)               Tel: +44 (0)20 7496 3000 
 Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance) 
 Mia Gardner (Corporate Broking) 
 
ICR, Inc. (US Media and Investor enquiries)                Tel: +1 203-919-7905 
 Darcie Robinson                                            mailto:Darcie.Robinson@icrinc.com Darcie.Robinson@icrinc.com 
 Stephanie Carrington                                       Tel. +1 646-277-1282 
                                                            mailto:Stephanie.Carrington@icrinc.com Stephanie.Carrington@icrinc.com 
                                                           ----------------------------------------------------------------------- 
 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, ensifentrine (RPL554), is a first-in-class, 
inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that 
has been shown to act as both a bronchodilator and an anti-inflammatory 
agent in a single compound. Ensifentrine is currently in Phase 2b 
clinical development for the maintenance treatment of COPD and is 
planned to enter Phase 3 trials for this indication in 2020. Verona 
Pharma is also developing ensifentrine for the treatment of cystic 
fibrosis and asthma. 
 
 
 
 

(END) Dow Jones Newswires

May 01, 2019 02:00 ET (06:00 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024

Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024